Search Within

David J Straus

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (37)
  2. Journal Article (24)
  3. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (62)
  2. Department of Medicine (62)
  3. Hematologic Malignancies, Division of (62)
  4. Lymphoma (62)
  5. Molecular Imaging and Therapy Service (62)
  6. Radiology, Department of (62)

More Groups

People
  1. Heiko Schoder (56)
  2. Andrew Zelenetz (46)
  3. Paul Hamlin (42)
  4. Ariela Noy (41)
  5. Matthew Matasar (40)
  6. Alison Moskowitz (39)

More People

Years
  1. 2024 (2)
  2. 2023 (4)
  3. 2022 (4)
  4. 2021 (8)
  5. 2020 (3)
  6. 2019 (5)

More Years

Publications
  1. Blood (31)
  2. Hematological Oncology (8)
  3. Journal of Clinical Oncology (8)
  4. Haematologica (4)
  5. Journal of Nuclear Medicine (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. American Society of Clinical Oncology (8)
  3. Wiley Blackwell (8)
  4. Ferrata Storti Foundation (4)
  5. Society of Nuclear Medicine (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (62)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results of US Intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (CALGB/Alliance 50604)
    Meeting Abstract

    Straus, D.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schöder, H.; Jung, S. H.; Popplewell, L.; Chang, J. E.; Moskowitz, C.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816
    Journal Article

    Press, O. W.; Li, H.; Schöder, H.; Straus, D. J.; Moskowitz, C. H.; LeBlanc, M.; Rimsza, L. M.; Bartlett, N. L.; Evens, A. M.; Mittra, E. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
    Journal Article

    Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB/Alliance 50604)
    Meeting Abstract

    Straus, D. J.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schoder, H.; Jung, S. H.; Popplewell, L. L.; Chang, J. E.; Moskowitz, C. H.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage III non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
    Journal Article

    Kostakoglu, L.; Schoder, H.; Johnson, J. L.; Hall, N. C.; Schwartz, L. H.; Straus, D. J.; LaCasce, A. S.; Jung, S. H.; Bartlett, N. L.; Canellos, G. P.; more...
    Leukemia and Lymphoma (2012)

    Fulltext@MSK | Save